Welcome to the ALiKE Study

Welcome to the ALiKE Study, a groundbreaking medical research initiative focused on improving long-term outcomes for lung transplant recipients. Lung transplantation has traditionally been limited by complications such as chronic organ rejection and associated conditions, notably kidney insufficiency due to the prolonged use of immunosuppressants. Our study is pioneering the use of Alemtuzumab for induction therapy followed by a low-dose, dual maintenance therapy to mitigate these risks.

This innovative approach aims to significantly reduce the nephrotoxic effects typically seen with standard Calcineurin inhibitors (CNIs), enhancing both kidney function and transplant acceptance. By integrating reduced doses of Tacrolimus with Everolimus, we not only lessen potential kidney damage but also bolster the recipient’s immune tolerance towards the transplanted organ.

Over the course of 24 months, the ALiKE Study will closely monitor 110 patients randomized into two groups to compare this novel protocol against the standard triple therapy regimen. Our primary endpoint is to observe the effects of this low-dose protocol on kidney function, specifically measuring changes in the estimated Glomerular Filtration Rate (eGFR).

Join us as we explore this new frontier in transplant medicine, aiming to extend the lives and improve the quality of life for those receiving lung transplants.